Fate Therapeutics (NASDAQ:FATE) Upgraded by StockNews.com to Hold Rating
Fate Therapeutics (NASDAQ:FATE – Get Free Report) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday. A number of other research firms have also issued reports on FATE. Wedbush reaffirmed a “neutral” rating and set a $5.00 target price on […]
Fate Therapeutics (NASDAQ:FATE – Get Free Report) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday. A number of other research firms have also issued reports on FATE. Wedbush reaffirmed a “neutral” rating and set a $5.00 target price on […]
